SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community rallies to maintain visibility and momentum while working through technical ticker issues on platform aggregators. Holders are actively coordinating on social channels to foster organic growth and build a long-term community project focused on sustainability and transparency.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market debate as investors weigh a recent FSD approval in the Netherlands against persistent concerns over shrinking margins and potential demand issues. While bulls point to vertical integration and future autonomous breakthroughs as long-term catalysts, the community is actively divided between those hunting for a major short squeeze and others bracing for further downside amid ongoing regulatory scrutiny.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community eagerly awaits the official reveal of the ES9 luxury SUV, which many expect to be a major catalyst for future growth and market share expansion. Investors are actively discussing the company's aggressive technological push and strong delivery momentum, fueling intense debate over potential institutional rotation and the ongoing battle between long-term bulls and short sellers.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is experiencing intense volatility following strong quarterly earnings that showcased solid revenue growth and increased customer adoption, yet the stock remains under pressure as investors weigh these fundamentals against sector-wide concerns regarding AI disruption and SaaS valuation resets. The community is actively debating whether the current sell-off represents an attractive buying opportunity for long-term growth or a structural repricing of high-multiple software companies facing increased competitive threats.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is currently experiencing extreme volatility and intense debate, with bulls citing a successful turnaround strategy and AI-driven edge demand while bears emphasize overvaluation and historical technical gaps. The stock has become a primary battleground for traders, with heavy discussion focused on its rapid ascent, frequent short-squeeze patterns, and skepticism regarding whether the recent price action is fueled by sustainable momentum or algorithmic distribution.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing significant market activity as investors react to a speculative but widely discussed 12-billion-dollar acquisition rumor involving Sun Pharma. While the company's substantial debt load and history of recurring takeover chatter are fueling skepticism among some, others are drawn to the stock's potential for a significant valuation reset if a deal materializes.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant investor attention as shares experience high volatility driven by speculation around upcoming pivotal trial data for its lead oncology candidate. The community is actively debating the company's valuation relative to its cash position, while split perspectives persist on whether the recent momentum represents a genuine breakout or a speculative short-term play.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a massive $21 billion contract expansion with Meta through 2032 and a new multi-year partnership with Anthropic to power its Claude AI models. While the community is excited about these major AI infrastructure wins and the company's deepening ties to industry leaders, sentiment is being tempered by concerns over the concurrent $3.5 billion convertible note offering and ongoing dilution fears.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors anticipate the upcoming topline Phase 2/3 OptimUM-02 trial results for its lead asset, darovasertib, in metastatic uveal melanoma. The community is actively discussing the potential for an accelerated approval filing and a commercial-stage transition, with many traders closely monitoring for high-volume price action and potential institutional accumulation ahead of the data release.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One...

Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush

Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday...

Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price target on shares of Cartesian Therapeutics in a report on Monday...

Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight

Cantor Fitzgerald raised Cartesian Therapeutics from a "neutral" rating to an "overweight" rating and set a $16.00 price target for the company in a research note on Monday...

Insights into Cartesian Therapeutics Q4 Earnings

Cartesian Therapeutics (RNAC) to Release Earnings on Thursday

Cartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat.com...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are currently covering the firm...

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm...

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company was founded on December 10, 2007 is headquartered in Frederick, MD.

RNAC
Selecta Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNAC News

RNACSelecta Biosciences Inc